Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.

Neeraj Narula Emily C L WongParambir S DulaiJohn K MarshallVipul JairathWalter Reinisch

Published in: The American journal of gastroenterology (2024)

Among patients with moderate-to-severe CD, early and delayed responders to adalimumab and ustekinumab have similar 1-year clinical outcomes. Biomarker decline can be observed through the initial 8 weeks of therapy in patients who will eventually be delayed responders, which may help differentiate from nonresponders.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
early onset
type diabetes
adipose tissue
systemic lupus erythematosus
bone marrow
disease activity
metabolic syndrome
drug induced